SWOG clinical trial number
CTSU/A051301

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype

Closed
Phase
Abbreviated Title
Phase III of ibrutinib vs placebo in relapsed or refractory DLBCL of the active b-cell subtype
Status Notes
A051301 has been permanently closed to accrual effective 12/20/2022.
Activated
07/06/2016
Closed
12/20/2022
Participants
CTSU

Research committees

Lymphoma

Treatment

Ibrutinib

Publication Information Expand/Collapse

2023

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

C Andreadis;O Bobek;E Hsi;T Fenske;S Geyer;P Stiff;B Till;M Horwitz;F Khimani;R Little;S Dinner;J Friedberg;B Kahl;M Perales;S Devine;J Leonard;N Bartlett ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
10%
Open
Phase